Form 4: Inmune Bio CFO David Moss Acquires 160,000 Stock Options

David Moss, CFO of Inmune Bio, Inc., reports the acquisition of 160,000 stock options on May 14, 2024.

Summary

• On May 16, 2024, David Moss, the Chief Financial Officer of Inmune Bio, Inc., filed a Form 4 with the SEC.
• The form reports a transaction that occurred on May 14, 2024, where Moss acquired 160,000 stock options.
• These options, granted under the 2021 Stock Incentive Plan, have an exercise price of $9.92.
• The options vest over four years, with one-fourth vesting after the first year and the remainder vesting monthly over the subsequent three years.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option grants. The CFO receiving options is generally a positive sign, but it's a routine occurrence.

Positives

• The acquisition of stock options by the CFO could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The granting of stock options aligns the CFO's interests with those of the shareholders, potentially incentivizing him to improve company performance.

Key Dates